Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Bionano Genomics, Inc. logo

NASDAQ · BNGO

Bionano Genomics, Inc.

Healthcare · Medical - Diagnostics & Research

$1.15

Down-$0.05 (-4.17%)

Updated Oct 31, 2026, 6:05 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.48M
P/E ratio
-0.23
Dividend yield
0.00%
52-week range
$1.00 – $2.23
Volume
196.43K
Avg. volume
721.42K

Price performance · BNGO

BNGO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BNGO closed at $1.15 after 21 trading sessions, down 22.30% for the selected period.

Last close
$1.15
Period change
-22.30%
Period low
$1.13
Period high
$1.48
Daily close
View OHLC price history
BNGO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.18$1.20$1.12$1.15196.43K
Oct 29, 2026$1.20$1.205$1.18$1.2067.19K
Oct 28, 2026$1.23$1.25$1.195$1.205114.37K
Oct 27, 2026$1.19$1.22$1.15$1.2273.59K
Oct 26, 2026$1.15$1.165$1.135$1.1662.37K
Oct 23, 2026$1.18$1.18$1.10$1.13251.96K
Oct 22, 2026$1.26$1.2997$1.17$1.18443.18K
Oct 21, 2026$1.26$1.28$1.25$1.25131.67K
Oct 20, 2026$1.21$1.32$1.21$1.245433.15K
Oct 19, 2026$1.27$1.2899$1.22$1.22133.41K
Oct 16, 2026$1.39$1.39$1.25$1.25181.14K
Oct 15, 2026$1.38$1.40$1.3303$1.3792.73K
Oct 14, 2026$1.37$1.4199$1.36$1.37158.29K
Oct 13, 2026$1.34$1.40$1.31$1.36187.15K
Oct 12, 2026$1.41$1.42$1.2903$1.345487.7K
Oct 9, 2026$1.45$1.50$1.4301$1.435129.4K
Oct 8, 2026$1.46$1.485$1.42$1.46182.73K
Oct 7, 2026$1.42$1.48$1.42$1.46134.08K
Oct 6, 2026$1.43$1.475$1.43$1.45208.5K
Oct 5, 2026$1.48$1.50$1.40$1.445322.91K
Oct 2, 2026$1.58$1.6199$1.451$1.48384.2K

Latest BNGO news

The latest Smart Investors Daily articles mentioning BNGO.

Stock researchCompany · Overview

BNGO research

Overview

Company profile and research snapshot.

Company profile

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$46.50
Implied upside
—
Analysts
—
BNGO recent ratings
DateFirmRatingTarget
Apr 13, 2026HC Wainwright & Co.Buy—
Nov 24, 2025HC Wainwright & Co.Buy—
Aug 18, 2025HC Wainwright & Co.Buy—
May 20, 2025Maxim GroupBuy—
Apr 9, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026

SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2026 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, November 10th, 2026Time:4:30 p.m. ETParticipant Link:Registration – click hereWebcast:Registration – click here Participants may access a live w

Yahoo · Sep 23, 2026

Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced expansion of optical genome mapping (OGM) based testing of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK), following approval from the New York State Department of Health (NYSDOH). Hematologic cancers, including acute leukemias, myelodysplastic syndromes (MDS),

Yahoo · Sep 14, 2026

Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasmsSAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today highlighted three new independently authored

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By